دورية أكاديمية
Allopurinol Prevents Cirrhosis-Related Complications: A Quadruple Blind Placebo-Controlled Trial.
| العنوان: | Allopurinol Prevents Cirrhosis-Related Complications: A Quadruple Blind Placebo-Controlled Trial. |
|---|---|
| المؤلفون: | Glal KAM; Department of Clinical Pharmacy, Faculty of Pharmacy. Electronic address: Khadija.ahmed@pharm.tanta.edu.eg., El-Haggar SM; Department of Clinical Pharmacy, Faculty of Pharmacy., Abdel-Salam SM; Department of Tropical Medicine and Infectious Diseases, Faculty of Medicine, Tanta University, Tanta, Egypt., Mostafa TM; Department of Clinical Pharmacy, Faculty of Pharmacy. |
| المصدر: | The American journal of medicine [Am J Med] 2024 Jan; Vol. 137 (1), pp. 55-64. Date of Electronic Publication: 2023 Oct 12. |
| نوع المنشور: | Randomized Controlled Trial; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Excerpta Medica Country of Publication: United States NLM ID: 0267200 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1555-7162 (Electronic) Linking ISSN: 00029343 NLM ISO Abbreviation: Am J Med Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: New York, NY : Excerpta Medica Original Publication: New York, Donnelly. |
| مواضيع طبية MeSH: | Esophageal and Gastric Varices*/complications , Hepatorenal Syndrome*/drug therapy , Hepatorenal Syndrome*/etiology , Hepatorenal Syndrome*/prevention & control , Peritonitis*/prevention & control , Peritonitis*/complications, Humans ; Allopurinol/therapeutic use ; Ascites/etiology ; Ascites/prevention & control ; Gastrointestinal Hemorrhage/etiology ; Liver Cirrhosis/complications |
| مستخلص: | Background: Complications associated with liver cirrhosis are various and potentially fatal. The treatment options to counteract hepatic decompensation are limited. Therefore, the study aimed to explore the use of allopurinol in preventing the recurrence of liver cirrhosis-related complications. Methods: One hundred patients with hepatic decompensation were randomized into 1:1 ratio to receive either allopurinol 300 mg or placebo tablets once daily for 6 months. The primary endpoint was the incidence of cirrhosis-related complications (overt ascites, spontaneous bacterial peritonitis, variceal bleeding, hepatorenal syndrome, and hepatic encephalopathy). Results: Six months following treatment, allopurinol reduced the relative risk (RR) of any first complication experienced after enrollment by 56% (hazard ratio [HR] 0.44; 95% confidence interval [CI], 0.27-0.62); P ˂ .001). Allopurinol decreased the RR of overt ascites by 67% (HR 0.33; 95% CI, 0.0098-0.94); P = .039] and reduced the RR of spontaneous bacterial peritonitis by about 75% (HR 0.25; 95% CI, 0.05-0.76; P = .01). Likewise, allopurinol was linked to an 80% reduction in the RR of developing hepatorenal syndrome (HR 0.2; 95% CI, 0.04-0.87; P = .033). Conclusion: Allopurinol significantly decreased the recurrence of overall liver cirrhosis-related complications. Therefore, allopurinol may constitute a promising agent for patients with hepatic decompensation. These positive outcomes could be a result of its ability to reduce bacterial translocation and inflammation. Gov Identifier: NCT005545670. (Copyright © 2023 Elsevier Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Allopurinol; Ascites; Cirrhosis; Decompensation |
| سلسلة جزيئية: | ClinicalTrials.gov NCT05545670 |
| المشرفين على المادة: | 63CZ7GJN5I (Allopurinol) |
| تواريخ الأحداث: | Date Created: 20231013 Date Completed: 20231216 Latest Revision: 20240723 |
| رمز التحديث: | 20240723 |
| DOI: | 10.1016/j.amjmed.2023.09.016 |
| PMID: | 37832758 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1555-7162 |
|---|---|
| DOI: | 10.1016/j.amjmed.2023.09.016 |